Oncology Institute (TOI) Competitors

$4.59 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.50 -0.09 (-1.96%)

As of 05/22/2026 07:58 PM Eastern

TOI vs. AGL, ARDT, AHCO, FTRE, and WGS

Should you buy Oncology Institute stock or one of its competitors? MarketBeat compares Oncology Institute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncology Institute include Agilon Health (AGL), Ardent Health (ARDT), AdaptHealth (AHCO), Fortrea (FTRE), and GeneDx (WGS). These companies are all part of the "healthcare" industry.

How does Oncology Institute compare to Agilon Health?

Agilon Health (NYSE:AGL) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Oncology Institute had 6 more articles in the media than Agilon Health. MarketBeat recorded 9 mentions for Oncology Institute and 3 mentions for Agilon Health. Oncology Institute's average media sentiment score of 1.79 beat Agilon Health's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilon Health	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncology Institute	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Agilon Health has a net margin of -6.09% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-6.09%	-146.03%	-24.55%
Oncology Institute	-7.42%	N/A	-24.68%

Oncology Institute has lower revenue, but higher earnings than Agilon Health. Oncology Institute is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.93B	0.24	-$391.35M	-$21.56	N/A
Oncology Institute	$502.73M	0.90	-$60.61M	-$0.37	N/A

Agilon Health presently has a consensus price target of $52.50, indicating a potential downside of 38.87%. Oncology Institute has a consensus price target of $7.00, indicating a potential upside of 52.51%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Agilon Health has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

36.9% of Oncology Institute shares are held by institutional investors. 2.3% of Agilon Health shares are held by company insiders. Comparatively, 8.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Oncology Institute beats Agilon Health on 10 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Ardent Health?

Ardent Health (NYSE:ARDT) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Ardent Health has a net margin of 2.09% compared to Oncology Institute's net margin of -7.42%. Ardent Health's return on equity of 13.85% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardent Health	2.09%	13.85%	4.48%
Oncology Institute	-7.42%	N/A	-24.68%

36.9% of Oncology Institute shares are held by institutional investors. 1.9% of Ardent Health shares are held by company insiders. Comparatively, 8.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ardent Health has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Ardent Health presently has a consensus price target of $14.21, suggesting a potential upside of 54.96%. Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 52.51%. Given Ardent Health's higher probable upside, equities analysts clearly believe Ardent Health is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardent Health	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.36
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ardent Health has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Ardent Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardent Health	$6.32B	0.21	$135.81M	$0.95	9.65
Oncology Institute	$502.73M	0.90	-$60.61M	-$0.37	N/A

In the previous week, Oncology Institute had 8 more articles in the media than Ardent Health. MarketBeat recorded 9 mentions for Oncology Institute and 1 mentions for Ardent Health. Oncology Institute's average media sentiment score of 1.79 beat Ardent Health's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardent Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncology Institute	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Ardent Health beats Oncology Institute on 10 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to AdaptHealth?

AdaptHealth (NASDAQ:AHCO) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

AdaptHealth has a net margin of -2.42% compared to Oncology Institute's net margin of -7.42%. AdaptHealth's return on equity of 2.76% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AdaptHealth	-2.42%	2.76%	0.99%
Oncology Institute	-7.42%	N/A	-24.68%

AdaptHealth currently has a consensus target price of $14.29, suggesting a potential upside of 36.71%. Oncology Institute has a consensus target price of $7.00, suggesting a potential upside of 52.51%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts plainly believe Oncology Institute is more favorable than AdaptHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AdaptHealth	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

82.7% of AdaptHealth shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 2.0% of AdaptHealth shares are held by insiders. Comparatively, 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oncology Institute has lower revenue, but higher earnings than AdaptHealth. AdaptHealth is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AdaptHealth	$3.24B	0.44	-$70.79M	-$0.62	N/A
Oncology Institute	$502.73M	0.90	-$60.61M	-$0.37	N/A

AdaptHealth has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

In the previous week, Oncology Institute had 9 more articles in the media than AdaptHealth. MarketBeat recorded 9 mentions for Oncology Institute and 0 mentions for AdaptHealth. Oncology Institute's average media sentiment score of 1.79 beat AdaptHealth's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
AdaptHealth	Neutral
Oncology Institute	Very Positive

Summary

Oncology Institute beats AdaptHealth on 9 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Fortrea?

Oncology Institute (NASDAQ:TOI) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Oncology Institute has a net margin of -7.42% compared to Fortrea's net margin of -16.50%. Fortrea's return on equity of 9.51% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Fortrea	-16.50%	9.51%	1.96%

Oncology Institute has higher earnings, but lower revenue than Fortrea. Oncology Institute is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	0.90	-$60.61M	-$0.37	N/A
Fortrea	$2.72B	0.46	-$986.20M	-$4.91	N/A

Oncology Institute has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by insiders. Comparatively, 0.4% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oncology Institute currently has a consensus price target of $7.00, suggesting a potential upside of 52.51%. Fortrea has a consensus price target of $17.25, suggesting a potential upside of 30.48%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Oncology Institute had 7 more articles in the media than Fortrea. MarketBeat recorded 9 mentions for Oncology Institute and 2 mentions for Fortrea. Oncology Institute's average media sentiment score of 1.79 beat Fortrea's score of 1.67 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncology Institute	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Oncology Institute beats Fortrea on 10 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to GeneDx?

Oncology Institute (NASDAQ:TOI) and GeneDx (NASDAQ:WGS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Oncology Institute has a net margin of -7.42% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
GeneDx	-17.58%	9.15%	5.21%

Oncology Institute has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, GeneDx has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market.

Oncology Institute currently has a consensus price target of $7.00, indicating a potential upside of 52.51%. GeneDx has a consensus price target of $96.43, indicating a potential upside of 103.82%. Given GeneDx's stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GeneDx has lower revenue, but higher earnings than Oncology Institute. GeneDx is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	0.90	-$60.61M	-$0.37	N/A
GeneDx	$427.54M	3.29	-$21.02M	-$2.68	N/A

In the previous week, GeneDx had 8 more articles in the media than Oncology Institute. MarketBeat recorded 17 mentions for GeneDx and 9 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.79 beat GeneDx's score of 0.70 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncology Institute	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GeneDx	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GeneDx beats Oncology Institute on 11 of the 16 factors compared between the two stocks.

Get Oncology Institute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TOI vs. The Competition

Export

Metric	Oncology Institute	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$453.67M	$8.38B	$6.46B	$12.34B
Dividend Yield	N/A	2.98%	2.76%	5.28%
P/E Ratio	-12.41	21.27	21.22	25.66
Price / Sales	0.90	19.11	562.28	86.31
Price / Cash	N/A	86.20	43.49	56.67
Price / Book	-28.69	5.84	10.31	7.14
Net Income	-$60.61M	$183.47M	$3.57B	$335.98M
7 Day Performance	11.95%	64.18%	6.43%	4.15%
1 Month Performance	41.23%	49.96%	3.57%	2.54%
1 Year Performance	51.99%	4.53%	34.07%	35.06%

Oncology Institute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TOI Oncology Institute	4.4271 of 5 stars	$4.59 flat	$7.00 +52.5%	+52.0%	$453.67M	$502.73M	N/A	660	Positive News Gap Down
AGL Agilon Health	1.4581 of 5 stars	$87.39 +0.7%	$45.05 -48.5%	+54.4%	$1.46B	$5.93B	N/A	1,076	Gap Down
ARDT Ardent Health	3.6448 of 5 stars	$9.80 -3.4%	$14.21 +45.1%	-37.2%	$1.40B	$6.32B	10.31	25,200
AHCO AdaptHealth	4.7249 of 5 stars	$10.33 -3.6%	$14.29 +38.3%	+19.0%	$1.40B	$3.24B	N/A	10,900
FTRE Fortrea	4.4371 of 5 stars	$13.71 +0.9%	$17.25 +25.8%	+225.6%	$1.30B	$2.72B	N/A	14,300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TOI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncology Institute (TOI) Competitors

TOI vs. AGL, ARDT, AHCO, FTRE, and WGS

How does Oncology Institute compare to Agilon Health?

Summary

How does Oncology Institute compare to Ardent Health?

Summary

How does Oncology Institute compare to AdaptHealth?

Summary

How does Oncology Institute compare to Fortrea?

Summary

How does Oncology Institute compare to GeneDx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncology Institute (TOI) Competitors

TOI vs. AGL, ARDT, AHCO, FTRE, and WGS

How does Oncology Institute compare to Agilon Health?

Does the media refer more to AGL or TOI?

Is AGL or TOI more profitable?

Which has better valuation and earnings, AGL or TOI?

Do analysts rate AGL or TOI?

Which has more risk and volatility, AGL or TOI?

Do institutionals and insiders have more ownership in AGL or TOI?

Summary

How does Oncology Institute compare to Ardent Health?

Is ARDT or TOI more profitable?

Do insiders & institutionals hold more shares of ARDT or TOI?

Which has more risk & volatility, ARDT or TOI?

Do analysts rate ARDT or TOI?

Which has preferable earnings and valuation, ARDT or TOI?

Does the media refer more to ARDT or TOI?

Summary

How does Oncology Institute compare to AdaptHealth?

Is AHCO or TOI more profitable?

Do analysts rate AHCO or TOI?

Do institutionals and insiders hold more shares of AHCO or TOI?

Which has stronger valuation and earnings, AHCO or TOI?

Which has more volatility & risk, AHCO or TOI?

Does the media prefer AHCO or TOI?

Summary

How does Oncology Institute compare to Fortrea?

Is TOI or FTRE more profitable?

Which has higher valuation & earnings, TOI or FTRE?

Which has more volatility & risk, TOI or FTRE?

Do institutionals & insiders have more ownership in TOI or FTRE?

Do analysts prefer TOI or FTRE?

Does the media favor TOI or FTRE?

Summary

How does Oncology Institute compare to GeneDx?

Is TOI or WGS more profitable?

Which has more volatility and risk, TOI or WGS?

Do analysts prefer TOI or WGS?

Do insiders and institutionals believe in TOI or WGS?

Which has stronger valuation & earnings, TOI or WGS?

Does the media favor TOI or WGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools